Logo

If Biogen Says No, Mr. Icahn, GTO Would Take $23 Billion

Oct 15, 2007

If you remember anyone who used to say that biotech would never amount to anything, now's the time to make the told-you-so phone call. Biogen Idec says it is considering a possible sale of the company, and one of the interested parties is Carl Icahn, who offered at least $23 billion, according to this article in the Wall Street Journal. Biogen Idec has a market cap of about $23.5 billion.

 

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.